Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06133322 · ClinicalTrials.gov registry record · NA

Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

A NA study of Hypertension, sponsored by Tulane University.

Recruiting
Registry status
NA
Development phase
1,176
Enrollment target
1
Study location

NCT06133322: Recruiting NA study of Hypertension, sponsored by Tulane University.

NCT06133322 is a NA study of Hypertension that is actively recruiting participants, run by Tulane University. The registered enrollment target is 1,176 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06133322, a NA study of Hypertension, is actively recruiting participants, sponsored by Tulane University.

RECRUITING
Registry status
NA
Development phase
1,176 participants
Enrollment target
1
Study location

Study Summary

The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test the effectiveness, implementation, and sustainability of a community health worker (CHW)-led multifaceted intervention compared to enhanced usual care for hypertension control in Black communities. In the BLESSED trial, the investigators plan to recruit 1,176 adults with hypertension (approximately 28 per church) from 42 predominantly Black churches in the Greater New Orleans area. The multifaceted intervention will last for 18 months, followed by a post-intervention follow-up visit at 24 months. The BLESSED trial aims to generate evidence regarding the effectiveness, implementation, and sustainability of this CHW-led church-based multifaceted intervention in eliminating hypertension disparities in the United States (US) general population.

Primary Outcome

Difference in mean change of systolic blood pressure from baseline to 18 months between intervention and control groups

Conditions Studied

Interventions

  • BEHAVIORAL Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline

Study Locations (1)

Louisiana

  • Tulane University - New Orleans

Trial Details

FieldValue
Enrollment Target 1,176 participants
Start Date 2023-11-01
Est. Completion 2027-06-30
Phase NA
Tulane University

73 total trials

What NCT06133322 shows while recruiting

NCT06133322 is an interventional study that assigns participants to a tested intervention. Its 1,176 participants enrollment target places it among the larger protocols in the corpus, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (66% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline is the first listed.

NCT06133322 reports a single indexed study location in Louisiana.

Frequently Asked Questions

What is clinical trial NCT06133322 about?

NCT06133322 is a clinical study titled "Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)". The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test ...

What is the current status of trial NCT06133322?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,176 participants. The study started on 2023-11-01. Estimated completion is 2027-06-30.

What conditions does trial NCT06133322 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT06133322?

The interventions under investigation include: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline (BEHAVIORAL).

Who is sponsoring clinical trial NCT06133322?

This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06133322 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06133322's enrollment target sits among peer trials

1,176 58th of 470 higher than 413 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05688436 · 1,178 participants

    A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

  • NCT06931275 · 1,178 participants · NA

    Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

  • NCT04275557 · 1,174 participants

    Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

  • NCT07286058 · 1,182 participants · Phase 3

    Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06133322, the US trial registry maintained by the National Library of Medicine. NCT06133322 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.